Wong Ee Woon, Bastian Liam, Wilcock Mike
Pharmacist All of Pharmacy Department, Royal Cornwall Hospitals NHS Trust, Truro, Cornwall, TR1 3LJ.
Lead Pharmacist for Digital Services All of Pharmacy Department, Royal Cornwall Hospitals NHS Trust, Truro, Cornwall, TR1 3LJ.
Br J Cardiol. 2022 Oct 11;29(4):32. doi: 10.5837/bjc.2022.032. eCollection 2022.
Dual antiplatelet therapy is recommended for secondary prevention of ischaemic events in coronary artery disease. Some patients, who may be at high bleed risk if other factors are present, should be considered for gastroprotection. In our survey, we assessed whether gastroprotection was prescribed for hospital inpatients, especially high-risk patients, who were receiving dual antiplatelet therapy at discharge, and the type of gastroprotection prescribed. We found that over 13 months, a total of 1,693 patient episodes were prescribed dual antiplatelet therapy at discharge, of which 71% also received gastroprotection. Of the patient episodes who were not prescribed gastroprotection, 46% (223/483) met the criterion of age as a risk factor for gastroprotection. A further 30 episodes met other risk criteria of certain concomitant drugs or prior comorbidity. There is a need among clinicians and pharmacy teams within the hospital for recognition and management of this opportunity to improve the care of these patients.
双联抗血小板治疗被推荐用于冠心病缺血事件的二级预防。如果存在其他因素，一些可能具有高出血风险的患者应考虑给予胃保护。在我们的调查中，我们评估了对于出院时接受双联抗血小板治疗的住院患者，尤其是高危患者，是否开具了胃保护药物以及所开具的胃保护药物类型。我们发现，在13个月的时间里，共有1693例患者在出院时被开具了双联抗血小板治疗，其中71%的患者还接受了胃保护。在未开具胃保护药物的患者中，46%（223/483）符合作为胃保护风险因素的年龄标准。另有30例符合某些合并用药或既往合并症的其他风险标准。医院内的临床医生和药学团队有必要认识并处理这一改善这些患者护理的机会。
